Most researchers looking for CJC-1295 in Kelso quickly find that local retail options are essentially nonexistent. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways local stores never could. What consistently distinguishes top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. This guide takes Kelso researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Kelso researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Where to Buy CJC-1295 — A Researcher's Guide
Evaluating CJC-1295 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at minute levels. Positive vendor signals beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Kelso
COA-verified · International tracking · Research grade
All use of CJC-1295 in Kelso or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. The research literature on CJC-1295 should be read critically before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
